David C. Kaslow
Plus aucun poste en cours
Profil
David C.
Kaslow, M.D., joined as Chief Scientific Officer in October 2001.
Dr. Kaslow has more than 15 years of vaccine research experience.
Dr. Kaslow joined Merck in February 1999 as Senior Director, Vaccine Research, and was employed by Merck, most recently as Head of the Department of Vaccine Research and Technology, until he joined Vical.
From 1986 to 1999, he held various senior research positions at the NIH, including Head of the Recombinant Protein Development Unit and the Malaria Vaccine Development Unit at the Laboratory of Parasitic Diseases.
Dr. Kaslow has been awarded numerous professional honors, including the U.S.
Public Health Service Outstanding Service Medal.
He has published more than 120 scientific papers, and authored more than 20 review articles and book chapters.
He holds or co-holds 13 patents.
Dr. Kaslow received his M.D.
from the School of Medicine at the University of California, San Francisco, in 1983 and his bachelor's degree from the University of California, Davis, in 1979.
Anciens postes connus de David C. Kaslow
Sociétés | Poste | Fin |
---|---|---|
Bank of America Private Bank
Bank of America Private Bank Investment ManagersFinance A subsidiary of Bank of America Corp. (NYSE: BAC), Boston-based Bank of America Private Bank (BAPB) offers private banking and wealth management services. | Gestionnaire de Portefeuille-Actions | 20/09/2005 |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de David C. Kaslow
The University of California, San Francisco | Doctorate Degree |
University of California, Davis | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Bank of America Private Bank
Bank of America Private Bank Investment ManagersFinance A subsidiary of Bank of America Corp. (NYSE: BAC), Boston-based Bank of America Private Bank (BAPB) offers private banking and wealth management services. | Finance |